Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
التاريخ
2017-12-01البيانات الوصفية
عرض كامل للتسجيلةالملخص
CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors
المجموعات
- أبحاث الطب [1508 items ]